Private Advisor Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-6,368
Closed -$737K 2564
2023
Q3
$737K Buy
6,368
+5
+0.1% +$537 0.01% 1193
2023
Q2
$654K Buy
6,363
+29
+0.5% +$3.06K 0.01% 1250
2023
Q1
$691K Buy
+6,334
New +$700K 0.01% 1178
2022
Q4
Sell
-6,481
Closed -$401K 2030
2022
Q3
$401K Sell
6,481
-80,537
-93% -$5.63M ﹤0.01% 1344
2022
Q2
$6.94M Buy
87,018
+42,278
+94% +$4M 0.06% 307
2022
Q1
$4.71M Sell
44,740
-27,174
-38% -$2.65M 0.04% 471
2021
Q4
$7.75M Sell
71,914
-42,282
-37% -$4.61M 0.06% 326
2021
Q3
$12.5M Buy
114,196
+50,156
+78% +$5.21M 0.08% 246
2021
Q2
$6M Buy
64,040
+4,997
+8% +$460K 0.05% 353
2021
Q1
$5.43M Buy
59,043
+7,587
+15% +$640K 0.05% 354
2020
Q4
$3.76M Buy
51,456
+41,431
+413% +$3.08M 0.04% 424
2020
Q3
$779K Buy
10,025
+601
+6% +$41.4K 0.01% 884
2020
Q2
$524K Hold
9,424
0.01% 1002
2020
Q1
$279K Buy
9,424
+545
+6% +$18.4K 0.01% 1102
2019
Q4
$321K Buy
+8,879
New +$272K 0.01% 1239

Other funds holding HZNP

Private Advisor Group's HZNP Position: Q4 2023 in Review

Private Advisor Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 6,368 shares — an estimated $737K sold.

Private Advisor Group first reported a position in HZNP in Q4 2019 and held it in 15 quarters. The position peaked at $12.5M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Private Advisor Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Private Advisor Group sold 6,368 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $737K.
  • Private Advisor Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 15 quarters.
  • Private Advisor Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $12.5M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Private Advisor Group's 13F filing for Q4 2023, filed 6 Feb 2024.